2024
Cell State Transition Models Stratify Breast Cancer Cell Phenotypes and Reveal New Therapeutic Targets
Rukhlenko O, Imoto H, Tambde A, McGillycuddy A, Junk P, Tuliakova A, Kolch W, Kholodenko B. Cell State Transition Models Stratify Breast Cancer Cell Phenotypes and Reveal New Therapeutic Targets. Cancers 2024, 16: 2354. PMID: 39001416, PMCID: PMC11240448, DOI: 10.3390/cancers16132354.Peer-Reviewed Original ResearchControl of cell movementCell linesCell statesLuminal BC cellsControl cell phenotypeWaddington landscapeTissue-derived cell linesCell movementOncogenic transformationSmall molecule inhibitorsSignaling nodeBC cell linesExpression profilesPerturbation datasetsNormal cell stateMolecule inhibitorsBC cellsCell phenotypeBasal BCBC subtypesBreast cancerOncogenic driversCellsCurrent biologicsBreast tissue cells
2018
PO-136 Studying pathway interactions and dynamics to predict cell responses to chemotherapeutic treatment in breast cancer cells
Tuffery L, Kholodenko B, Kolch W, Halasz M, Fey D. PO-136 Studying pathway interactions and dynamics to predict cell responses to chemotherapeutic treatment in breast cancer cells. ESMO Open 2018, 3: a279. DOI: 10.1136/esmoopen-2018-eacr25.660.Peer-Reviewed Original ResearchBreast cancer cell linesDoxorubicin treatmentCancer cell linesCell linesDifferent breast cancer cell linesBreast cancer cellsMCF10A cellsDifferent mutation patternsMechanism of actionPhosphorylation of JNKBreast cancer tumor samplesCommon cancerPatient responseTreatment strategiesBreast cancerTreatment responseChemotherapeutic treatmentCell responsesFlow cytometryTumor samplesWestern blotNon-cancerous cellsChemotherapeutic drugsPathway interactionsCancer cells
2016
HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
Weitsman G, Barber PR, Nguyen LK, Lawler K, Patel G, Woodman N, Kelleher MT, Pinder SE, Rowley M, Ellis PA, Purushotham AD, Coolen AC, Kholodenko BN, Vojnovic B, Gillett C, Ng T. HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Oncotarget 2016, 7: 51012-51026. PMID: 27618787, PMCID: PMC5239455, DOI: 10.18632/oncotarget.9963.Peer-Reviewed Original ResearchConceptsGroup of patientsMetastatic relapsePredictive biomarkersHER2 proteinHER2 IHC statusOnly predictive biomarkerInvasive breast cancerNovel prognostic biomarkerOverexpression of HER2Important prognostic markerBreast cancer tissuesHistology-based analysisSignificant clinical utilityHER2-HER3 dimersIHC statusHER2 expressionTissue microarray coresPrognostic markerBreast cancerPrognostic biomarkerHER2-HER3 heterodimersClinical utilityCancer tissuesTumor progressionDriver of proliferation